Key Highlights

  • IJK tracks the S&P MidCap 400 Growth index with 249 holdings focused on U.S. mid-cap growth equities.
  • NAV was $103.44 as of 19 November 2026, with net Assets of approximately $9.92 billion.
  • The expense ratio is 0.16%, with a 30-day SEC Yield of 0.67% and a 12-month trailing yield of 0.59%.
  • TechnipFMC, United Therapeutics, and ATI lead the portfolio, each exceeding 1.4% of fund weight.

The iShares S&P Mid-Cap 400 Growth ETF (NYSEARCA:IJK), managed by BlackRock, seeks to track the S&P MidCap 400 Growth Index, a benchmark of U.S. mid-cap stocks selected using growth metrics such as above-average Earnings and Revenue growth. Launched on 24 July 2000, the fund holds 249 securities as of 19 November 2026, with net assets of approximately $9.92 billion.

Fund Name

iShares S&P Mid-Cap 400 Growth ETF

Ticker

NYSEARCA:IJK

Benchmark Index

S&P MidCap 400 Growth Index

NAV (as of 19 November 2026)

$103.44

Net Assets

$9.92 billion

Number of Holdings

249

Expense Ratio

0.16%

30-Day SEC Yield

0.67%

12-Month Trailing Yield

0.59%

P/E Ratio

25.81

P/B Ratio

4.23

Equity Beta (3-Year)

1.06

Distribution Frequency

Quarterly

Fund Inception

24 July 2000

Portfolio Structure and Leading Positions

IJK's 249-security portfolio offers targeted exposure to the growth segment of the S&P MidCap 400. TechnipFMC leads at 1.50% of market weight, followed by United Therapeutics at 1.49%, ATI at 1.48%, and Tenet Healthcare at 1.32%. XPO (1.32%), Woodward (1.23%), and Royal Gold (1.22%) round out the top seven positions. The Industrials sector is notably well represented, with several leading holdings drawn from that segment.

The sector composition features significant allocations to Industrials, Health Care, Energy, and Information Technology. The fund distributes income quarterly, with the September 2026 distribution at $0.192931 per share. Exchange-traded Index Futures may be used to offset cash and receivables for index-tracking purposes.

Valuation and Risk Metrics

The portfolio carries a price-to-earnings ratio of 25.81 and a Price-to-Book Ratio of 4.23, reflecting the growth-oriented selection methodology. The three-year Equity beta of 1.06 indicates sensitivity to broader market movements that is close to the market average, while the Standard Deviation of 15.92% represents the Volatility profile of mid-cap growth investing.

As of 19 November 2026, IJK's NAV was $103.44 and the closing price was $103.47, with a premium/discount of 0.03. The 30-day median bid-ask spread was 0.04%, and the 30-day average Volume was 340,542 shares. The expense ratio of 0.16% is competitive within the mid-cap growth ETF category.

Yield and Distribution Characteristics

The 30-day SEC yield was 0.67% as of 31 October 2026, with a 12-month trailing yield of 0.59%. These yield levels are typical for growth-focused mid-cap equities, where companies generally reinvest a larger share of earnings. Quarterly distributions in 2026 have ranged from approximately $0.10 to $0.19 per share.

IJK trades on NYSE Arca with 95,950,000 shares outstanding. The S&P MidCap 400 Growth Index selects constituents from the broader S&P MidCap 400 using metrics that include three-year earnings and sales growth alongside price momentum.

Final Word

The iShares S&P Mid-Cap 400 Growth ETF provides targeted access to 249 growth-oriented mid-cap U.S. equities at a 0.16% expense ratio. The fund's Industrials-heavy top holdings and near-market beta distinguish its profile within the mid-cap growth category. With nearly $10 billion in net assets and consistent quarterly distributions, IJK occupies a well-established position in the mid-cap growth ETF landscape.